14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

Heat Biologics Stock Forecast

NASDAQ:HTBX Delisted Open a Brokerage Account

$2.38 (0%)

Volume: 0

Closed: Aug 17, 2022

Hollow Logo Score: 0.000

Heat Biologics Stock Forecast

$2.38 (0%)

Volume: 0

Closed: Aug 17, 2022

Score Hollow Logo 0.000

Heat Biologics Stock News NASDAQ:HTBX

Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives Read more

Heat Biologics reports 2021 revenue $2.1M, consensus $2.11M

01:06pm, Monday, 14'th Mar 2022 Seeking Alpha
Heat Biologics (HTBX) has presented favorable survival data at The American Association of Cancer Research of HS-110 in combination with checkpoint inhibitors for the treatment… Read more

Heat Biologics to move to NYSE from Nasdaq

09:34pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Heat Biologics (HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market.Heat expects to begin trading on NYSE under its Read more

Heat Biologics Announces Planned Transfer to the NYSE American

09:05pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modula Read more
Elusys Therapeutics, which is being acquired by Heat Biologics <>, said it finalized a contract with the U.S Read more
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Read more

Heat Biologics (HTBX) Investor Presentation - Slideshow

06:43pm, Friday, 28'th Jan 2022 Seeking Alpha
Read more
Heat Biologics Inc (NASDAQ: HTBX ) announced promising preclinical data regarding PTX-35 . The data has been accepted for publication in the American Journal of Transplantation. A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory T cells (Tregs) and significantly improved disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted Full story available on Benzinga.com Read more
DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation and is available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16940 . Key Findings : A single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly improve disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted with beta-cell islet allografts and treated with mPTX-35. Disease protection in preclinical models was correlated with a significant expansion of Tregs and protection of the allograft, resulting in euglycemia and a graft survival benefit. Long-term surviving grafts showed a marked increase in Treg infiltration which directly correlated with mPTX-35 agonist activity. Read more
Heat Biologics Inc (HTBX) shares closed 3.6% lower than its previous 52 week low, giving the company a market cap of $83M. The stock is currently down 38.4% year-to-date, down 41.1% over the past 12 months, and down 94.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 53.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -218.4% The company's stock price performance over the past 12 months lags the peer average by -225.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

12:30pm, Tuesday, 21'st Dec 2021 GlobeNewswire Inc.
Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S. Read more

State Street Corp Increases Position in Heat Biologics, Inc. (NASDAQ:HTBX)

09:22am, Sunday, 05'th Dec 2021 Dakota Financial News
State Street Corp increased its stake in Heat Biologics, Inc. (NASDAQ:HTBX) by 466.5% in the 2nd quarter, Holdings Channel reports. The fund owned 98,896 shares of the biopharmaceutical companys stock after buying an additional 81,440 shares during the quarter. State Street Corps holdings in Heat Biologics were worth $666,000 at the end of the most [] Read more
In last trading session, Heat Biologics Inc. (NASDAQ:HTBX) saw 0.32 million shares changing hands with its beta currently measuring 0.23. Companys recent per share price level of $3.93 trading at -$0.24 or -5.76% at ring of the bell on the day assigns it a market valuation of $99.63M. That closing price of HTBXs stock is Heat Biologics Inc. (NASDAQ:HTBX) -13.44% Down Over A Week, Can The Stock Hit Well Above -$0.61? Read More » Read more
Designed for rapid plug and play programming and stockpiling against emerging infectious agents and viral mutations Read more
Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Read more

Hot Stocks To Watch:

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE